Peter J Boström

List of Publications by Year
in descending order

151 papers	4,097 citations	109137 35 h-index	149479 56 g-index
154 all docs	154 docs citations	154 times ranked	5885 citing authors

#	ARTICLE	IF	CITATIONS
1	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. Journal of Clinical Oncology, 2017, 35, 2299-2305.	0.8	241
2	Genomic Predictors of Outcome in Prostate Cancer. European Urology, 2015, 68, 1033-1044.	0.9	166
3	A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. European Urology, 2012, 61, 378-384.	0.9	144
4	Risk factors for mortality and morbidity related to radical cystectomy. BJU International, 2009, 103, 191-196.	1.3	133
5	Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multiâ€‘institutional study. Journal of Magnetic Resonance Imaging, 2017, 46, 184-193.	1.9	114
6	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multiâ€‘institutional study. BJU International, 2011, 108, 24-30.	1.3	111
7	Nutraceuticals and prostate cancer prevention: a current review. Nature Reviews Urology, 2010, 7, 21-30.	1.9	101
8	Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU International, 2012, 110, 804-811.	1.3	96
9	The <i>FGFR3</i> Mutation is Related to Favorable pT1 Bladder Cancer. Journal of Urology, 2012, 187, 310-314.	0.2	85
10	Patients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer. European Urology, 2013, 63, 379-385.	0.9	85
11	Secondary Cancer After Radiotherapy for Prostate Cancer: Should We Be More Aware of the Risk?. European Urology, 2007, 52, 973-982.	0.9	79
12	Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization. PLoS ONE, 2019, 14, e0217702.	1.1	76
13	Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). Journal of Magnetic Resonance Imaging, 2017, 46, 1089-1095.	1.9	75
14	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2014, 66, 628-632.	0.9	72
15	Evaluation of different mathematical models for diffusion-weighted imaging of normal prostate and prostate cancer using high b-values: A repeatability study. Magnetic Resonance in Medicine, 2015, 73, 1988-1998.	1.9	72
16	Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. European Urology, 2019, 76, 586-595.	0.9	68
17	Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 355-364.	3.3	66
18	Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU International, 2011, 108, E237-E244.	1.3	62

#	Article	IF	Citations
19	Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder. International Journal of Cancer, 2000, 88, 417-423.	2.3	58
20	A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). European Urology Oncology, 2021, 4, 635-644.	2.6	58
21	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. European Urology, 2020, 78, 682-687.	0.9	57
22	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). European Urology Oncology, 2021, 4, 971-979.	2.6	56
23	Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer. PLoS ONE, 2015, 10, e0133552.	1.1	55
24	Staging and Staging Errors in Bladder Cancer. European Urology Supplements, 2010, 9, 2-9.	0.1	53
25	Prognostic value of molecular markers, subâ€stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU International, 2012, 110, 1169-1176.	1.3	53
26	Mathematical models for diffusionâ€weighted imaging of prostate cancer using b values up to 2000 s/mm^2: Correlation with Gleason score and repeatability of region of interest analysis. Magnetic Resonance in Medicine, 2015, 74, 1116-1124.	1.9	53
27	Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nature Reviews Urology, 2010, 7, 311-325.	1.9	49
28	SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nature Communications, 2019, 10, 2340.	5.8	49
29	Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction. Magnetic Resonance in Medicine, 2017, 77, 1249-1264.	1.9	48
30	Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. Modern Pathology, 2016, 29, 1565-1574.	2.9	43
31	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Medicine, 2019, 16, e1002813.	3.9	43
32	Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. PLoS ONE, 2016, 11, e0155901.	1.1	43
33	Bladder Cancer After Radiotherapy for Prostate Cancer: Detailed Analysis of Pathological Features and Outcome After Radical Cystectomy. Journal of Urology, 2008, 179, 91-95.	0.2	42
34	Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naÃ¯ve prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 665-673.	3.3	42
35	Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression. PLoS ONE, 2015, 10, e0140671.	1.1	39
36	Urinary Bladder Transitional Cell Carcinogenesis Is Associated with Down-Regulation of NF1 Tumor Suppressor Gene in Vivo and in Vitro. American Journal of Pathology, 1999, 154, 755-765.	1.9	38

#	Article	IF	Citations
37	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. Journal of Urology, 2016, 196, 1627-1633.	0.2	36
38	Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells. Pathology, 2001, 33, 469-474.	0.3	33
39	Non-muscle-invasive bladder cancer: a vision for the future. Scandinavian Journal of Urology, 2017, 51, 87-94.	0.6	33
40	Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy. Bladder Cancer, 2016, 2, 101-109.	0.2	31
41	ANO7 is associated with aggressive prostate cancer. International Journal of Cancer, 2018, 143, 2479-2487.	2.3	31
42	Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. European Urology, 2019, 76, 430-434.	0.9	31
43	Lack of Decorin Expression by Human Bladder Cancer Cells Offers New Tools in the Therapy of Urothelial Malignancies. PLoS ONE, 2013, 8, e76190.	1.1	30
44	Does patient age affect survival after radical cystectomy?. BJU International, 2012, 110, E486-93.	1.3	28
45	Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols. World Journal of Urology, 2013, 31, 161-167.	1.2	28
46	Long-term Outcome of Patients with Frequently Recurrent Non–muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomised FinnBladder-4 Study. European Urology, 2015, 68, 611-617.	0.9	27
47	Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis, 2019, 40, 84-92.	1.3	27
48	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. European Urology Focus, 2018, 4, 995-1001.	1.6	26
49	Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2951-2959.	3.3	26
50	Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. Urology Annals, 2011, 3, 119.	0.3	23
51	FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 207-213.	1.4	23
52	Diffusion-weighted imaging of prostate cancer: effect of b-value distribution on repeatability and cancer characterization. Magnetic Resonance Imaging, 2015, 33, 1212-1218.	1.0	23
53	Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy. International Journal of Cancer, 2016, 139, 140-152.	2.3	23
54	Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non–Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. European Urology, 2016, 70, 341-347.	0.9	23

#	Article	IF	Citations
55	Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study. European Urology Oncology, 2018, 1, 525-530.	2.6	23
56	Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. Scandinavian Journal of Urology, 2019, 53, 295-302.	0.6	23
57	Repeatability of radiomics and machine learning for DWI: Shortâ€term repeatability study of 112 patients with prostate cancer. Magnetic Resonance in Medicine, 2020, 83, 2293-2309.	1.9	23
58	Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. BJU International, 2012, 109, 70-76.	1.3	22
59	11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial). Cancer Imaging, 2018, 18, 25.	1.2	22
60	Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRIâ€Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTIâ€IMPROD Trials). Journal of Magnetic Resonance Imaging, 2020, 51, 1556-1567.	1.9	22
61	Risk factors associated with positive surgical marginsâ€™ location at radical cystectomy and their impact on bladder cancer survival. World Journal of Urology, 2021, 39, 4363-4371.	1.2	22
62	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 110.e1-110.e9.	0.8	22
63	Interferon-Î± inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. Urological Research, 2001, 29, 20-24.	1.5	21
64	Time trends and occupational variation in the incidence of testicular cancer in the Nordic countries. BJU International, 2018, 122, 384-393.	1.3	21
65	Global expression of AMACR transcripts predicts risk for prostate cancer â€" a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. BMC Urology, 2016, 16, 10.	0.6	19
66	Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. European Urology Oncology, 2020, 3, 648-656.	2.6	18
67	New prostate cancer grade grouping system predicts survival after radical prostatectomy. Human Pathology, 2018, 75, 159-166.	1.1	17
68	Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre. Scandinavian Journal of Urology and Nephrology, 2009, 43, 357-364.	1.4	16
69	Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care. Scandinavian Journal of Urology, 2016, 50, 149-154.	0.6	16
70	Rotating frame relaxation imaging of prostate cancer: Repeatability, cancer detection, and Gleason score prediction. Magnetic Resonance in Medicine, 2016, 75, 337-344.	1.9	16
71	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. Scientific Reports, 2017, 7, 12682.	1.6	16
72	Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. Endocrine-Related Cancer, 2018, 25, 807-819.	1.6	16

#	Article	IF	Citations
73	Prediction of complication related death after radical cystectomy for bladder cancer with machine learning methodology. Scandinavian Journal of Urology, 2019, 53, 325-331.	0.6	16
74	IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy. Journal of Magnetic Resonance Imaging, 2019, 50, 1641-1650.	1.9	16
75	Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort. European Urology Focus, 2019, 5, 443-448.	1.6	16
76	Salvage Magnetic Resonance Imaging–guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results. European Urology Open Science, 2020, 22, 79-87.	0.2	16
77	High-Intensity Physical Activity, Stable Relationship, and High Education Level Associate with Decreasing Risk of Erectile Dysfunction in 1,000 Apparently Healthy Cardiovascular Risk Subjects. Journal of Sexual Medicine, 2014, 11, 2277-2284.	0.3	15
78	Relaxation along fictitious field, diffusion-weighted imaging, and T_2 mapping of prostate cancer: Prediction of cancer aggressiveness. Magnetic Resonance in Medicine, 2016, 75, 2130-2140.	1.9	15
79	Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study. World Journal of Urology, 2020, 39, 1879-1887.	1.2	15
80	Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps. European Radiology, 2021, 31, 379-391.	2.3	15
81	Antibiotic susceptibility of intestinal *Escherichia coli* in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study. BJU International, 2018, 122, 203-210.	1.3	14
82	Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. EJNMMI Research, 2019, 9, 50.	1.1	14
83	Progress towards a Nordic standard for the investigation of hematuria: 2019. Scandinavian Journal of Urology, 2019, 53, 1-6.	0.6	14
84	Protodynamic therapy for bladder cancer: *in vitro* results of a novel treatment concept. BJU International, 2009, 104, 1233-1238.	1.3	13
85	Tournament leave-pair-out cross-validation for receiver operating characteristic analysis. Statistical Methods in Medical Research, 2019, 28, 2975-2991.	0.7	13
86	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. European Urology Oncology, 2021, 4, 289-296.	2.6	13
87	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. Npj Precision Oncology, 2021, 5, 35.	2.3	13
88	Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA. Acta Oncológica, 2017, 56, 971-977.	0.8	11
89	The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis. Prostate, 2018, 78, 583-594.	1.2	11
90	Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (*eCancerCare^Bladder*): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 835-841.	2.2	10

#	Article	IF	Citations
91	The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland. International Journal of Cancer, 2018, 142, 891-898.	2.3	10
92	A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. Scientific Reports, 2021, 11, 8650.	1.6	10
93	Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3723-3731.	3.3	10
94	Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. European Urology Focus, 2021, 7, 522-531.	1.6	10
95	Adverse Events During Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Bladder Cancer, 2019, 5, 273-279.	0.2	9
96	Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial. World Journal of Urology, 2020, 38, 1001-1007.	1.2	9
97	Magnetic resonance imaging–guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12‐month clinical outcomes of a phase I study. BJU International, 2022, 129, 208-216.	1.3	9
98	Detection of Prostate Cancer Using Biparametric Prostate MRI, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. Journal of Magnetic Resonance Imaging, 2022, 55, 465-477.	1.9	9
99	Optimal timing of radical cystectomy in T1 high-grade bladder cancer. Expert Review of Anticancer Therapy, 2010, 10, 1891-1902.	1.1	8
100	Stratification of aggressive prostate cancer from indolent disease—Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 255.e15-255.e22.	0.8	8
101	External Validation of a Biomarker Based Pre-Cystectomy Algorithm to Predict Nonorgan Confined Urothelial Cancers. Journal of Urology, 2012, 187, 840-844.	0.2	7
102	Seminal vesicles and urinary bladder as sites of aromatization of androgens in men, evidenced by a CYP19A1‐driven luciferase reporter mouse and human tissue specimens. FASEB Journal, 2013, 27, 1342-1350.	0.2	7
103	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. Bladder Cancer, 2016, 2, 263-272.	0.2	7
104	ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. Anticancer Research, 2019, 39, 5353-5359.	0.5	7
105	Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer. Scandinavian Journal of Urology, 2020, 54, 481-486.	0.6	7
106	The variant rs77559646 associated with aggressive prostate cancer disrupts ANO7 mRNA splicing and protein expression. Human Molecular Genetics, 2022, 31, 2063-2077.	1.4	7
107	Erectile dysfunction cannot be used in primary screening of pre-diabetes. Diabetes Research and Clinical Practice, 2015, 108, e60-e62.	1.1	6
108	Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates. BMC Urology, 2015, 15, 88.	0.6	6

#	Article	IF	Citations
109	Diffusion weighted imaging of prostate cancer: Prediction of cancer using texture features from parametric maps of the monoexponential and kurtosis functions. , 2016, , .		6
110	Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. International Journal of Hyperthermia, 2019, 36, 914-924.	1.1	6
111	Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer. Acta Radiologica, 2020, 62, 028418512097693.	0.5	6
112	Awareness of Smoking as a Risk Factor in Bladder Cancer: Results from the Prospective FinnBladder 9 Trial. European Urology Focus, 2022, 8, 1246-1252.	1.6	6
113	Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 16.e1-16.e7.	0.8	5
114	Vasectomy and the risk of prostate cancer in a Finnish nationwide population-based cohort. Cancer Epidemiology, 2020, 64, 101631.	0.8	5
115	Visual MRI T-category versus VI-RADS evaluation from multiparametric MRI in the detection of muscle-invasion in patients with suspected bladder cancer: single centre registered clinical trial (MIB-trial). Scandinavian Journal of Urology, 2021, 55, 354-360.	0.6	5
116	Incidence of and mortality from Bacille Calmetteâ€‰uÃ©rin (BCG) infections after BCG instillation therapy. BJU International, 2022, 129, 737-743.	1.3	5
117	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Open, 2022, 12, e050264.	0.8	5
118	Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmetteâ€‰uÃ©rin (BCG) treatment. BJU International, 2019, 123, 246-251.	1.3	4
119	Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 80-80.	0.8	4
120	Upper Urinary Tract Cancerâ€"Challenges for the Urologist. Journal of Urology, 2007, 178, 12-13.	0.2	3
121	Bulbourethral gland adenocarcinoma in a 25-year-old man without comorbidities: Radical resection of proximal urethrae with Mitrofanoff-type appendicovesicostomy. Scandinavian Journal of Urology, 2014, 48, 405-409.	0.6	3
122	Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method. Journal of Magnetic Resonance Imaging, 2016, 44, 1405-1414.	1.9	3
123	Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy. Scientific Reports, 2016, 6, 36161.	1.6	3
124	Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machineâ€‰earning Techniques. Journal of Magnetic Resonance Imaging, 2020, 51, 1540-1553.	1.9	3
125	Critical evaluation of the subcutaneous engraftments of hormone naÃ¯ve primary prostate cancer. Translational Andrology and Urology, 2020, 9, 1120-1134.	0.6	3
126	Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. Scientific Reports, 2020, 10, 9407.	1.6	3

#	Article	IF	Citations
127	Clinical markers of morbidity, mortality and survival in bladder cancer patients treated with radical cystectomy. A systematic review. Scandinavian Journal of Urology, 2020, 54, 267-276.	0.6	3
128	Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. Scientific Reports, 2021, 11, 13684.	1.6	3
129	Uptake of ^{18}F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 205-213.	0.7	3
130	Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers. Acta Radiologica, 2023, 64, 1228-1237.	0.5	3
131	Decreased forced expiratory volume in first second is associated with erectile dysfunction in apparently healthy men. A preliminary study.. International Journal of Impotence Research, 2020, 32, 420-425.	1.0	2
132	Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430–4: Can Patient-derived Cancer Models Change the Costliest Cancer Type?. European Urology, 2020, 77, e23.	0.9	2
133	Reply to Joshua S. Jue and Mahmoud Alameddine's Letter to the Editor re: Juha Knaapila, Ivan Jambor, Ileana Montoya Perez, et al. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. Eur Urol Oncol 2020;3:648–656. European Urology Oncology, 2020, 3, 711-712.	2.6	2
134	Familial aggregation of testicular cancer among early-onset cancer survivors. A prospective observational cohort data from Finland. Cancer Epidemiology, 2020, 69, 101807.	0.8	2
135	Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy. International Journal of Molecular Sciences, 2020, 21, 7420.	1.8	2
136	Response to the Letter to the Editor: Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2672-2673.	3.3	2
137	Computerized histomorphometric features of glandular architecture predict risk of biochemical recurrence following radical prostatectomy: A multisite study.. Journal of Clinical Oncology, 2019, 37, 5060-5060.	0.8	2
138	Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression. Cancers, 2022, 14, 278.	1.7	2
139	Reply from Authors re: Robert S. Svatek. Long-term Outcomes of the FinnBladder-4 Study. Eur Urol 2015;68:618–9. European Urology, 2015, 68, 619-620.	0.9	1
140	Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430–4. European Urology, 2019, 76, e137-e138.	0.9	1
141	Re: Antonio C. Westphalen, Charles E. McCulloch, Jordan M. Anaokar, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology 2020;296:76–84. European Urology Oncology, 2020, 3, 714-715.	2.6	1
142	Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2016, 34, 393-393.	0.8	1
143	How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database. Acta Radiologica Open, 2021, 10, 205846012110607.	0.3	1
144	Fiducial markers and their impact on ablation outcome for patients treated with MR-guided transurethral ablation (TULSA): a retrospective technical analysis. International Journal of Hyperthermia, 2021, 38, 1677-1684.	1.1	1

#	Article	IF	Citations
145	Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD) Tj ETQq1 1 0.784314 rgBT1/Overlock		
146	Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen. journal of applied laboratory medicine, The, 2019, 3, 1014-1021.	0.6	0
147	Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naÃ¯ve men. Scandinavian Journal of Urology, 2020, 54, 7-13.	0.6	0
148	Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation. BMC Urology, 2020, 20, 25.	0.6	0
149	Which data are available in central registries on bladder cancer patients in the five Nordic countries. Scandinavian Journal of Urology, 2021, 55, 135-141.	0.6	0
150	A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic.. Journal of Clinical Oncology, 2017, 35, e16003-e16003.	0.8	0
151	Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study. World Journal of Urology, 2022, , 1.	1.2	0